10. Lucemyra

US WorldMeds Lucemyra product shot
(US WorldMeds and Salix)

Active ingredient: lofexidine hydrochloride 
Disease: opioid withdrawal symptoms 
Peak sales: N/A  
Approved: May 16 
Company: US WorldMeds

The scoop: Excruciating symptoms of opioid withdrawal can prevent people addicted to opioids from getting off the painkillers. Lucemyra, which has been used for more than two decades in the U.K., was approved to help make the withdrawal process easier for U.S. patients. The drug itself isn’t meant to treat opioid addiction or curb drug cravings. But it can be used as part of a long-term plan toward eventually quitting opioids. National Institute on Drug Abuse Director Nora Volkow, M.D., argues that it could boost wider use of Alkermes’ Vivitrol, a nonopioid addiction treatment that blocks the intoxication effects, by helping patients stick to the detoxification therapies. Lucemyra is currently approved for no more than 14 days of treatment, but more studies are underway, including examining its long-term use. US WorldMeds signed a deal with Bausch Health’s Salix Pharmaceuticals to co-promote Lucemyra. The pair launched the drug in August with a copay program that provides it to eligible patients for as little as $25. — Angus Liu

10. Lucemyra

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.